News and Trends 23 May 2018 Another Pneumonia Antibiotic is Close to Treating Patients Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2018 Celgene Partners With German Biotech to Develop Oncology Treatments Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […] May 22, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 21 May 2018 Engineering Red Blood Cells to Fight the Most Severe Cancers Our very own red blood cells could soon become a treatment for some of the most severe forms of cancer; After a long journey of ups and downs, Erytech is now near the finish line to launch the first red blood cell therapy. How amazing would it be if we could use our own cells […] May 21, 2018 - 6 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 18 May 2018 This French Biotech Targets Retinal Cells to Treat Blindness Today, we’re in Paris, visiting SparingVision, a biotech trying to combat blindness using a protein that slows down the degeneration of cone cells in the retina. Mission: SparingVision uses a naturally occurring protein called rod-derived cone-viability factor, which binds to a transmembrane peptide on cone photoreceptor cells in the retina and allows more glucose to enter […] May 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 17 May 2018 The First In-Human Trial of an Eye Implant Helps Patients With Glaucoma iSTAR Medical has obtained promising results from the first-in-human trial of an eye implant, that can decrease fluid pressure in the eyes of glaucoma patients. iSTAR Medical, a Belgian biotech, has six-month results from a first-in-human trial showing the effects of its device on intraocular pressure in patients with glaucoma — a condition where high eye […] May 17, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2018 Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […] May 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2018 Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […] May 16, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2018 Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for its treatment for acute graft-versus-host disease, a complication of stem cell transplants. Xenikos has raised a substantial Series B fundraising round to conduct Phase III trials in the US and the EU for T-Guard, its treatment for steroid-resistant acute graft […] May 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2018 Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance Polyphor has closed an IPO of CHF 165M (€138M) to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX Swiss Exchange, surpassing its initial goal of CHF150M (€127M). The funds will […] May 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 11 May 2018 This Oxford Biotech is Using DNA to Find New Peptide Drugs Today, we’re in Oxford, UK, visiting Orbit Discovery. The biotech develops peptide drugs for chronic diseases using DNA to tag potential therapeutic proteins. Mission: Orbit Discovery develops peptide drugs for a range of conditions including metabolic, autoimmune and cardiovascular diseases using beads to connect peptides to the DNA that encodes them and see how well the peptides […] May 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email